These functional roles in the TME may be specific to left-sided subtypes in colon cancer and DCLK1 may have potential as a prognostic biomarker and adjuvant target to promote immunotherapy sensitivity to improve outcomes in colon and gastric cancer patients. This evidence concerns the gene DCLK1 and colonic neoplasm.